Literature DB >> 15073704

Milrinone and nitric oxide: combined effect on pulmonary artery pressures after cardiopulmonary bypass in children.

Vadim Khazin1, Yefim Kaufman, Deeb Zabeeda, Beniamin Medalion, Lior Sasson, Arie Schachner, Tiberiu Ezri.   

Abstract

OBJECTIVE: To investigate the effect of milrinone combined with nitric oxide (NO) on the pulmonary artery pressures (PAP) after cardiopulmonary bypass (CPB), for repair of congenital heart defects (CHD) in children.
DESIGN: Prospective, randomized, double-blind study.
SETTING: University affiliated community hospital. PARTICIPANTS: Ninety children with pulmonary hypertension and repair of CHD.
INTERVENTIONS: After weaning from CPB, patients (30 in each group) received 3 drug regimens: group 1, nitric oxide (NO); group 2, a continuous infusion of milrinone; and group 3, a combination of the 2. Drugs were started after CPB and given for 20 minutes.
MEASUREMENTS AND MAIN RESULTS: Pulmonary and systemic pressures, PaCO(2), SaO(2), and pH values were recorded before bypass, after weaning from CPB, 10 and 20 minutes after starting each regimen, and 10 minutes after the cessation of treatment. Mean systemic blood pressure was lower (p < 0.05) in the combined treatment group after discontinuation of the drugs. Although mean PAP values were lower in the combined group (p < 0.05), no difference was recorded with regard to pH, PaCO(2), and PaO(2). The ratio between pre- and post-treatment mean PAP was highest in group 3(1.26 +/- 0.5) and lowest in group 2 (0.99 +/- 0.3, p < 0.001). The mean PAP recorded after discontinuation of the drug was lower than the baseline value in groups 1 and 3 (p < 0.05).
CONCLUSIONS: The combination of milrinone and NO produced a more pronounced decrease in PAP than milrinone alone.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15073704     DOI: 10.1053/j.jvca.2004.01.020

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  13 in total

Review 1.  Management of acute right ventricular failure in the intensive care unit.

Authors:  Eric M Green; Michael M Givertz
Journal:  Curr Heart Fail Rep       Date:  2012-09

Review 2.  [Treatment of acute and chronic right ventricular failure].

Authors:  T Kramm; S Guth; C B Wiedenroth; H A Ghofrani; E Mayer
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-05-30       Impact factor: 0.840

Review 3.  The role of milrinone in children with cardiovascular compromise: review of the literature.

Authors:  Sascha Meyer; Ludwig Gortner; Kate Brown; Hashim Abdul-Khaliq
Journal:  Wien Med Wochenschr       Date:  2011-03-07

4.  Treatment of premature infants with pulmonary hypertension and right ventricular dysfunction with milrinone: a case series.

Authors:  A T James; C Bee; J D Corcoran; P J McNamara; O Franklin; A F El-Khuffash
Journal:  J Perinatol       Date:  2014-11-27       Impact factor: 2.521

5.  Milrinone attenuates thromboxane receptor-mediated hyperresponsiveness in hypoxic pulmonary arterial myocytes.

Authors:  K T Santhosh; O Elkhateeb; N Nolette; O Outbih; A J Halayko; S Dakshinamurti
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

Review 6.  Right ventricular failure: a comorbidity or a clinical emergency?

Authors:  Pamelika Das; Rajarajan A Thandavarayan; Kenichi Watanabe; Ravichandiran Velayutham; Somasundaram Arumugam
Journal:  Heart Fail Rev       Date:  2021-11-26       Impact factor: 4.654

7.  Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn.

Authors:  Satyan Lakshminrusimha; Nicolas F M Porta; Kathryn N Farrow; Bernadette Chen; Sylvia F Gugino; Vasanth H Kumar; James A Russell; Robin H Steinhorn
Journal:  Pediatr Crit Care Med       Date:  2009-01       Impact factor: 3.624

8.  Management Practice and Mortality for Infants with Congenital Diaphragmatic Hernia.

Authors:  Jonathan R Malowitz; Christoph P Hornik; Matthew M Laughon; Daniela Testoni; C Michael Cotten; Reese H Clark; P Brian Smith
Journal:  Am J Perinatol       Date:  2015-02-25       Impact factor: 3.079

9.  Effect of preoperative oral sildenafil on severe pulmonary artery hypertension in patients undergoing mitral valve replacement.

Authors:  Hemang Gandhi; Bipin Shah; Ramesh Patel; Rajesh Toshani; Jigisha Pujara; Jignesh Kothari; Naman Shastri
Journal:  Indian J Pharmacol       Date:  2014 May-Jun       Impact factor: 1.200

10.  Additive effect of phosphodiesterase inhibitors in control of pulmonary hypertension after congenital cardiac surgery in children.

Authors:  Peiravian Farah; Amirghofran Ahmad-Ali; Ghamsari Hanane; Emaminia Abbas
Journal:  Iran J Pediatr       Date:  2013-02       Impact factor: 0.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.